Ignite Creation Date:
2024-05-06 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 2:28 PM
Study NCT ID:
NCT05291052
Status:
UNKNOWN
Last Update Posted:
2022-03-22
First Post:
2022-03-14
Brief Title:
Tisleizumab Combined With Lenvatinib and XELOX Regimen Oxaliplatin Combined With Capecitabine in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-02-14
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-03-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-03-14
First Submit QC Date:
March 14 2022
Study First Post Date:
2022-03-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-03-14
Last Update Post Date:
2022-03-22
Last Update Post Date Type:
ACTUAL